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Pre-market regulation of the introduction of new medical products is
widely seen as offerinc the important beneEit of protecting the public from
the hazards of potentially unsafe drugs and devices (Mitchell and Link, 1976).
At the same time, many believe these regulations unduly delay or prevent the
availability of new products by imposing added costs on the process of tech-
nical innovation (Mitchell and Link, 1976; Wardell, 1979). Much of the inter-
est in the latter issue stems from response to the legislative changes enacted
in 1962 by the U.S. Congress that gave the Food and Drug Administration (FDA)
the authority to impose safety and efficacy criteria on new commercial pharma-
ceutical product review prior to market introduction. A general decline in
U.S. drug research and development in the ten years that followed has been de-
scribed as a "biological knowledge gap" and attributed by some, but not all, to
the costs of compliance with the newly-imposed regulations (Wardell, 1979;
Pelzman, 1973).
By the recent enactment of the Medical Device Amendments of 1976, Congress
extended the mandate of the FDA to require additional scrutiny of non-pharmaceut-
ical commercial products with clinical applications (P.L. 94-295). Un-
certainties about how new laws will be implemented continue to complicate the
estimation of the magnitude any added costs to be incurred by would-be manu-
facturers of new device and diagnostic products. Hence, it is unlikely that
either these costs, or the countervailing benefits of the regulations can eas-
ily be quantified or compared.
Instead we have adopted an historical approach in order to consider the
likely effects of safety and efficacy regulation on the process of technolo-
gical innovation in medical devices. Previously reported work has addressed
the stages of the innovation process that precede commercialization and has
empirically documented the significance of both commercial and non-commercial
sources in the generation of new products (von Hippel,,1976, 1977, 1979; von
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Hippel and Finkelstein, 1979; Comroe and Dripps, 1976). The predominance of
one source relative to the other has relevance for the impact of regulation
on medical device innovation because the regulations promulgated are designed
to have a direct effect on the commercial manufacturers of medical devices only.
In this paper, we first describe the Medical Device Amendments of 1976.
Next, we provide empirical evidence on the sources of a subset of the innova-
tions regulated by the Amendments clinical chemistry diagnostic products andf
finally, we discuss the likely effect of the Amendments given the pattern of
the innovation found.
The Medical Device Amendments of 1976
The Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act
became law in 1976. These amendments assigned broad authority to the food and
drug administration to establish procedures and safeguards governing the intro-
duction and usage of a broad class of products called "Medical Devices."* Com-
pliance with the regulations is principally demanded of commercial manufacturers
intent on introducing new products and only secondarily concerned with modifica-
tions to products and procedures occuring outside the manufacturers control.
The device amendments authorize the FDA to classify all devices into one
of three categories. These categories reflect the risks associated with the
degree of critical application of the device. Class 1 devices would be the
least stringently regulated, subject to "general controls" including the re-
gistration by each manufacturer of those production facilities manufacturing
* It would be inaccurate to state that prior to the 1976 laws, medical devices
were absolutely free of regulation. Some diagnostic technologies, for ex-
ample, made use of antibiotic drugs and were considered drugs for regulatory
purposes. Diagnostics derived from animal or human blood called biologicals
would have been regulated under specific authority for this category of sub-
stances. In addition, hospitals or other locations undertaking human test-
ing of new devices would cost likely have been subject to review by that
institutions committee that monitors research on human subjects.
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specific devices. Manufacturers of class 1 devices are required to comply
with "good manufacturing practices" (GMPs) and also required to establish
staffs responsible for compliance with the GMPs. Inspections of manufact-
uring facilities to verify manufacturer compliances are mandated for class
1 devices. Class 2 devices are those for which the general controls described
above were seen to present insufficient safety assurance. Specific standards
of performance for each device classified in this category were to be agreed
on by members appointed to advisory panels of the Bureau of Devices in the FDA.
Devices categorized in class 3 require pre-market approval to be granted on
the basis of studies of the safety and efficacy of the device. Upon the grant-
ing of pre-market approval, class 3 devices are reclassified into one of the
less stringent risk categories (class 2 or class 1).
All products which were on the market at the same time of enactment of
the amendments were to be considered tentatively classified in class 1, pend-
ing the establishment of standards for products that were seen to belong in
class 2. Products introduced after the enactment date but shown to be sub-
stantially equivalent to products already on the m4rket at the time of en-
actment may be marketed according to regulations for equivalent products if
this equivalency can be satisfactorily documented. However, post enactment
devices bearing no equivalence relationship to products currently on the
market will automatically fall into class 3. Pre-market approval is required
for any manufacturer introducing a device for the first time whether or not
another manufacturer is already marketing a similar product. Significant
changes in design or modifications in the use of device also necessitate pre-
market review.
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Because a number of critical regulations have yet to be promulgated, the
Medical Device Amendments present considerable uncertainty to affected manu-
facturers. Some estimates are that it will be at least two more years before
the various panels commissioned by the FDA complete their respective classifi-
cation activities. The regulations as implemented will offer an opportunity
for challenging a classification or the denial by the FDA of "substantially
equivalent" status. Also permitted will be "investigational device exemptions"
which would permit product testing by a supervised clinical investigator. How-
ever many of the procedures for challenges and exemptions have yet to be promul-
gated.
With uncertainty about the magnitude of any increases in costs or develop-
ment time for new products comes special concern for small firms for whom
lengthened development time might present a cash drain to organizations that
would already be expected to be hard pressed for working capital. In an effort
to assist small manufacturers, the FDA has established an office of Small Manu-
facturer Assistance. It has placed medical device coordinators at regional FDA
offices and offers publications, workshops, and assorted advisory materials.
While these efforts may help the small manufacturer understand how to comply
with the regulations, they do not at all diminish his responsibility for compliance.
Direct costs of compliance with regulation would seem to be dependent
on whether a particular device or diagnostic is assigned to class 1, 2, or 3
(Glennie and Dworkin, 1975). One description of current devices that has
been reported by the FDA has about one-third classified as "general controls"
(class 1) and nearly one-half as "performance standards," (class 2, leaving
some 17% as potentially requiring pre-market approval (class 3). The per-
cent of diagnostics, the device category that we will explore at length, re-
quiring pre-market clearance by the FDA would be expected to be even low-
er. And some argue that reputable manufacturers would incur the costs
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of generating clinical product-evaluation data on most of these products in
the absence of any federal requirement.
It has also been argued that the high pportunity costs of developing
new devices or diagnostics that require pre-market approval might be high
enough that firms conducting research and development might shift their
focus to concentrate on developing less critical products or making improve-
ments to current products. Some have predicted a general decline in research
activity while others have stated their belief that the growth rate in the
device area in recent years has been so great and financial incentives so
strong that if a decline in research output does occur, that it will not be
large.
If safety and efficacy regulation makes it more difficult to introduce un-
safe and unworthy new clinical products to market, then it might also be more
difficult and more costly to introduce ones that are safe and effective. How
much protection from potential hazard is worth trading for how much new pro-
duct innovation is a judgment call that will not be settled without lengthy de-
bate. We will later argue that only if the historical pattern of innovation in
the clinical chemistry diagnostic products area strongly favors a private sec-
tor locus to the essential exclusion of public sector sources will the impact
of the new regulations on chemistry innovation be as destructive as the pessi-
mists predict.
The Source of Clinical Chemistry Test Innovations
Accurate determination of the source of innovations is not a trivial un-
dertaking. Since we clearly could not undertake to determine the source of
innovation for all medical "Devices" regulated under the 1976 Amendments, we
elected to concentrate on innovations in clinical chemistry tests performed
on automated equipment only. This decision was not derived from theoretical
insight. Rather, two eminently practical considerations were determining:
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1) One of the authors (S.F.) is a physician specializing in clinical
chemistry.
2) A great deal of product innovation has takeni place in the category
in the last 20 years.
In this section we will present empirical data regarding the patterns
of innovation found in clinical chemistry tests. We will begin by briefly
characterizing such tests for readers unfamiliar with them. We will then
describe the two samples of test-related innovations we have studied; des-
cribe how data regarding these was collected; and then, finally present the
innovation patterns observed.
Clinical chemistry tests are used by physicians to determine the level
of a chemical, such as glucose, in a patient's blood. Typically there are
several "methods" available by which a particular "test" (such as blood glu-
cose) can be performed. The execution of a clinical chemistry test method
involves combining a sample of a patient's serum with one or more reagents
and then allowing the chemical reaction(s) thus initiated to take place under
prescribed conditions of time and temperature. Substances which would inter-
fere with the test measurement are removed (by precipitation, dialysis, or
other means), the test measurement is made (via techniques such as colorimetry
or fluorometry) and the test result recorded. Since the 1950's, automated
clinical chemistry analyzer equipment has been available which, as the name
implies, can carry out clinical chemistry tests automatically.
Typically, the first version of a new chemical test method to be devel-
oped is a 'manual' one - a protocol which may be executed by a clinical che-
mist using standard laboratory techniques and equipment. Later, some of
these manual methods are adapted for use on automated equipment. We decided
to examine patterns of innovation in both of these tasks.
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Our sample of adaptations of clinical chemistry tests for use on auto-
mated equipment was assembled via the following steps. First, the 20 chemi-
cal tests most frequently performed in 1977 were identified; next, the two
manufacturers of automated clinical chemistry test analyzers with the largest
number of units in place in hospital clinical chemistry labs in 1977 were
identified - Technicon and DuPont (IMS America Ltd., 1977); finally, test
methods currently recommended by Technicon and DuPont for use on their most
recently commercialized models* of analyzer equipment were dentified via tech-
nical literature supplied by these two manufacturers.
DuPont was found to offer automated methods for 18 of the 20 clinical
chemistry tests most frequently performed in 1977 and Technicon was found to
offer automated methods for performing all 20.** Since adaptation to automa-
tion is an. innovatiQn task which is performed anew, for analyzers utilizing
different principles of operation - and Technicon and DuPont auto-analyzers
do Qperate pn different principles - the sample selection process outlined
above gave us a sample of 38 cases of the "adaptation to automation" innovation
task to analyze.
Qqr sample of manually performed clinical chemistry tests were selected
tQ be. the manual test protocols which were the antecedents to the sample of
autQpated tests described above, (Study of each of the automated protocols
sampled showed that all were based on manual protocols described earlier.).
* Technicon's latest model is trade-named the "SMAC High Speed Computer-Controlled
Biochemical Analyzer". The only model DuPont has ever introduced--and thus its
latest model--is trade-named "ACA--Automated Clinical Analyzer".
** The identity of these twenty tests: Albumin; Alk Phos; Calcium; Chloride;
Cholesterol; CPK; Creatinine; Direct (conjugated Bilirubin; Glucose; SGOT;
SGPT; Inorganic Phos; LDH; Potassium; Sodium; Total Protein; Triglycerides;
Urea Nitrogen; Uric Acid. (All 20 are offered by Technicon; DuPont offers
all by potassium and sodium).
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In many instances, the Duont and Technicon automated methods recommended in
1977 by these manufacturers for performance of a given test were found to be
based on the same manual protocol. When such duplications were omitted, we
were left with a sample of 24 cases of the innovation task "development of a
manually-performed clinical chemistry test method which was later adapted for
automation."
Data regarding the patterns of innovative activity associated with our
innovation sample was collected by, first, conducting a search of the medical
literature* for publications related to each innovation being examined. We
then contacted authors whose work was regarded by us - or cited in other papers
as - importantly contributing to each innovation. Those contacted were given
semi-structured interviews regarding their knowledge of innovation pattern
issues of interest to us. In the course of these interviews, interviewees were
asked for the names of other individuals with user, manufacturer, or other re-
lationships to the innovation who might have a good knowledge of these matters
discussed. Individuals so identified were contacted in turn, and the process
continued by iteration until we felt a point of dimihishing returns had been
reached.
In a second and independent data collection effort, manufacturer person-
nel involved in commercializing automated chemistry innovations who might not
have published or have been known to those who had published were contacted
* During our literature searches, two data sources were found to be especially
useful. The MEDLINE computerized index of the medical literature and "Product
Labeling"--U.S. Food and Drug Administration terminology for methods-related
information which the suppliers of clinical test chemistry methods make avail-
able to their customers. We acquired product labeling from both Technicon and
Dupont for all tests and methods in our sample. These contained references
to publications on chemical test methods used and, in the case of Technicon
labeling, also contained references to publication reporting innovations in
basic chemical methods as well as adaption of methods to automation and the
results.
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and interviewed. We felt such individuals could potentially have useful addi-
tional data and a very different point of view regarding the innovation patterns
leading to the innovations being studied.
For the purposes of the present paper, the main finding of interest to
us, developed from the approach described above, is that both commercial
and non-commercial sources of innovation were indeed found present in our
innovation samples. These are shown in Figure 1. Note from the data pre-
sented in the figure that almost all of the manual test protocols later adapted
for automated execution on the Technicon SMAC and the DuPont aca were developed
by workers at non-profit institutions. Note further that most of the adapt-
ation of methods to Technicon equipment - but not DuPont equipment - was per-
formed at non-profit institutions. (In a separate article (von Hippel and
Finkelstein, 1979) we have carefully explored the interbrand difference in
observed innovation pattern and have determined that these are caused by dif-
ferences in the design of the two brands of clinical chemistry analyzer, which
make it considerably easier for researchers to implement test adaptions on the
former than on the latter. In essence, the Technicon analyzer equipment is
modular and utilizes reagent reservoirs which are accessible to the operator.
This means that a researcher interested in adapting a novel test to the equip-
ment can connect up the analyzer modules in a novel configuration and/or in-
sert novel reagents in the equipments supply reservoirs. In contrast, the
DuPont aca is not modular and utilizes reagent contained in factory sealed






























Figure 1: Sources of Clinical Chemistry Test Innovation
Notes: (a) Coded 'non profit' if method developer(s) determined to
be employed by a hospital, university or institute while
doing the method development work.
(b) Coded 'manufacturer' if method developer(s) determined to
be employed by a manufacturer of clinical chemistry analyzer
equipment and/or manufacturer of reagents used in these while
doing the method development work.
(c) The coding 'method developer' was assigned to the first to
publish a report of the method and clinical data regarding
its validity. ('Publication' the case of manufacturers, could
be either journal publication or the date of first marketing
of the method (usually in the form of reagent 'kits' for
manual or machine applications). Test methods are not marketed
until supporting clinical data is available).
(d) The SMAC is the latest of several models of Technicon Analyzers
utilizing the principle of "continuous flow analysis". Some
of the methods offered by Technicon to SMAC users were adapted
to continuous flow on the SMAC, others were adapted on other
models of continuous flow analyzers and found appropriate for





Our original premise had been that extrapolation from the experience
following the 1962 changes in drug regulation in order to predict the im-
pact of the 1976 device laws on innovation might yield misleading results.
This is because the sources of innovation could very well have been differ-
ent in medical device innovation than in drug innovation. Below, we con-
sider the significance of the sources of innovation we found in clinical
chemistry test methods.
In the concrete instance of clinical chemistry diagnostic products,
we have shown that researchers and practitioners working in non-profit
institutions dominated the origins of the tests in our sample although
laboratories of commercial manufacturers originated some new manually-
executed clinical chemistry tests and adapted more of these to automated
equipment. With respect to modifications, we typically found that when
a manual chemistry test method was developed by a manufacturer, the adapt-
ation to instrumentation was also undertaken by that same manufacturer.
On the other hand, when a manual chemistry test method was developed by a
user, it was adapted to automation by the same or another user or alterna-
tively in a manufacturer's laboratory.
Implementation of the medical device amendments is proceeding with com-
pliance being demanded principally from manufacturers who wish to sell novel
test methods. The amendments set no specific requirements for those who
develop test methods which are not sold commercially - but which are or can
be used for diagnostic purposes by clinical laboratories. It appears that
research conducted in non-profit laboratories will be, for the most part, un-
affected because the researchers' incentives have not been changed by the new
laws. When we interviewed hospital based physicians, we found them to be
-12-
virtually unconcerned with the Device Amendments and did not see them as
barriers to their own inovative activity. This is probably because re-
searchers active in this3 area are motivated chiefly by factors such as
intellectual curiosity nd producing and publishing research results lead-
ing recognition by academic peers. Economic rewards would have only minor
significance here. In contrast, because compliance is costly for manufact-
urers, we can anticipate that implementation of the Medical Device Amend-
ments of 1976 may result in a reduction of clinical chemistry test innova-
tion from this source.
In sum, then, our findings lead us to suspect that the negative im-
pact of the Medical Device Amendments on research into innovative clinical
chemistry tests will be moderated by the lack of impact of these regulations
on the source of most such innovations - researchers and practitioners work-
ing in non-profit institutions. But what about the impact of the regulation
on dissemination of such innovations? Our research. did not address the patterns
of dissemination of clinical chemistry innovations, However, we suspect that
manufacturers play a major role in diffusion and that only a relatively few
sophisticated labs implement an innovative test on the basis of reports in
the literature, Thus, we may suspect that the Medical Device Amendments will
have a much more significant impact on diffusion than on research - at least
in the short run. In the longer run, it is interesting to speculate whether
non-commercial diffusion might increase as a response on the part of users to
increased delays in delivery of the latest technology through commercial chan-
nels due to the new regulations. If so, this would affect the commercial fate
of different brands of analyzers. Those capable of using user-prepared re-
agents would fare best, and could also have the effect of circumventing a
principal intent of the Medical Device Amendment, preventing consumer access
Ill
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to unapproved "Medical Devices". Whether such a prospect is to be feared
or welcomed will depend on each reader's view of the likely cost versus
benefit of the regulation introduced with the Medical Device Amendments of
1976. We suggest only that studies of the sources of innovation such as
that performed here can potentially allow readers to raise specific questions
regarding the likely impact of proposed new regulations on innovation at
the time the regulations are being designed.
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